GPBP is a protein kinase for the non collagenous-1 domain of the α3 chain of type IV collagen [α3(IV)NC1], a principal component of glomerular and alveolar filtration barriers.

Español | English     

Home

Company

Overview GPBP Corporate objectives Scientific advisory board News

Research & Development

Patent portfolio

Partnership & licensing

Contact

Overview

FibroStatin SL is a biotech company focused on the development of Goodpasture antigen-binding protein (GPBP) technology for research and medical purposes.

FibroStatin SL was founded in 2005 by researchers from the Centro de Investigación Príncipe Felipe (formerly Instituto de Investigaciones Citológicas) and the University of Valencia, and is located at the Scientific Park of University of Valencia.

FibroStatin SL holds exclusive intellectual property on GPBP-related technology through a number of international issued and pending patents.

 

 

Founders of FibroStatin, S.L.

Juan Saus; MD, PhD.

Head of the Laboratory of Autoimmune Pathology at the Centro de Investigación Príncipe Felipe in Valencia, Spain.

Associate Professor at the Department of Biochemistry and Molecular Biology of the University of Valencia.

Fernando Revert, PhD. Valencia, Spain.

Francisco Revert, PhD. Valencia, Spain.